Journal: Frontiers in Immunology

Article Title: Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging

doi: 10.3389/fimmu.2024.1383932

Figure Lengend Snippet: Immunophenotyping panel for multiplexed tissue imaging of cancer.

Article Snippet: CD39 , REA739 , 50 , 130-110-650 , PE , Miltenyi Biotec.

Techniques: Imaging

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation

doi: 10.1007/s00262-023-03416-4

Figure Lengend Snippet: The expression of tumor CD73 was significantly associated with the risk of distant metastasis after surgical operation and poor survival outcome. A CD73 proteins were mainly expressed on the membrane of cancer cells. CD39 proteins were majorly expressed in the stromal cells and partially expressed in the inflammatory cells. B The H-score of tumor CD73 was statistically associated with the risk of distant metastasis (n = 421 and unpaired T-test p = 0.0353). C Stromal CD39 expression was not associated with the present of LVI, PNI and distant metastasis (n = 421) by unpaired T-test. D Tumor CD73 expression was significantly associated with pathological T stage (n = 421, p = 0.0008). Stromal CD39 expression was not associated with pathological T stage (n = 421 and p = 0.70). One-way ANOVA test. E Patients with high tumor CD73 expression were clinically associated with worsen disease-free survival (DFS) in CRC patients (n = 421, p = 0.0076). High stromal CD39 expression was associated with favorable DFS in CRC patients (n = 421 p = 0.0034). F Tumor CD73 expression was significantly associated with distant metastasis-free survival (DMFS) and DFS in stage II-III COAD patients who received adjuvant chemotherapy (n = 177, log-rank p = 0.0077). G Tumor CD73 expression was conversely associated with the density of CD8+ TILs and CD45.+ TILs within tumor microenvironment (TME). Unpaired t test (n = 421)

Article Snippet: After incubation with the primary rabbit monoclonal antibody against CD73 (#13,160, 1:100, Cell Signaling Tech.) or CD39 (#14,481, 1:100, Cell Signaling Tech.) at room temperature for 2 h, the sections were stained according to the manufacture’s manual (VECTASTAIN Elite ABC Kit, Vector Laboratories) and incubated with the substrate DAB chromogen (Vector Laboratories), and then were counterstained with hematoxylin [ 21 , 22 ].

Techniques: Expressing, Membrane, Adjuvant

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation

doi: 10.1007/s00262-023-03416-4

Figure Lengend Snippet: Correlation between clinicopathologic parameters, DFS and OS

Article Snippet: After incubation with the primary rabbit monoclonal antibody against CD73 (#13,160, 1:100, Cell Signaling Tech.) or CD39 (#14,481, 1:100, Cell Signaling Tech.) at room temperature for 2 h, the sections were stained according to the manufacture’s manual (VECTASTAIN Elite ABC Kit, Vector Laboratories) and incubated with the substrate DAB chromogen (Vector Laboratories), and then were counterstained with hematoxylin [ 21 , 22 ].

Techniques:

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation

doi: 10.1007/s00262-023-03416-4

Figure Lengend Snippet: Univariate and multivariate analysis of DFS and known prognostic factors in stage I-IV colon adenocarcinoma patients

Article Snippet: After incubation with the primary rabbit monoclonal antibody against CD73 (#13,160, 1:100, Cell Signaling Tech.) or CD39 (#14,481, 1:100, Cell Signaling Tech.) at room temperature for 2 h, the sections were stained according to the manufacture’s manual (VECTASTAIN Elite ABC Kit, Vector Laboratories) and incubated with the substrate DAB chromogen (Vector Laboratories), and then were counterstained with hematoxylin [ 21 , 22 ].

Techniques:

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation

doi: 10.1007/s00262-023-03416-4

Figure Lengend Snippet: Genomic correlates of NT5E and CD8 signatures in the TCGA dataset A CD73/NT5E was highly expressed on tumor tissues compared to normal tissues. B High CD73 mRNA expression was remarkably associated with poor survival outcome in CRC patients that retrieved from TCGA database (cut-off mRNA = 9.0, n = 368, p = 0.0453). Moreover, CD39 mRNA expression was not associated with poor survival outcome in CRC patients that retrieved from TCGA database (cut-off mRNA = 3.37, n = 515, p = 0.7079). C High CD73 mRNA expression was conversely associated with less expression of T-cell mediated signatures (TCGA database, n = 368, unpaired T test). ***p < 0.001

Article Snippet: After incubation with the primary rabbit monoclonal antibody against CD73 (#13,160, 1:100, Cell Signaling Tech.) or CD39 (#14,481, 1:100, Cell Signaling Tech.) at room temperature for 2 h, the sections were stained according to the manufacture’s manual (VECTASTAIN Elite ABC Kit, Vector Laboratories) and incubated with the substrate DAB chromogen (Vector Laboratories), and then were counterstained with hematoxylin [ 21 , 22 ].

Techniques: Expressing

Journal: Cancer Immunology Research

Article Title: CD161 characterizes an inflamed subset of cytotoxic T lymphocytes associated with prolonged survival in human papillomavirus-driven oropharyngeal cancer

doi: 10.1158/2326-6066.cir-22-0454

Figure Lengend Snippet: Figure 4. The phenotype and function of CD161þ CTLs. A, Heat map displaying expression values of discriminative genes between KLRB1 and KLRB1þ CTLs (from clusters 0, 2, 3, and 9) based on the data from single-cell RNA sequencing. B, Scores for the terminal exhaustion signature, tissue-resident memory T-cell signature, and chemokine/IFNg signature in KLRB1 and KLRB1þ CTLs based on the data from single-cell RNA sequencing. C, Coexpression of cytotoxic cytokines and inhibitory receptors on CD161 or CD161þ CTLs in OPSCC biopsies (n ¼ 13–19) via flow cytometry, paired Student t test. D, MFI of cytotoxic cytokines coexpressed on CD161 or CD161þ CTLs treated with PD-1 or CD39 blocking antibodies in OPSCC biopsies (n ¼ 7–8), paired Student t test. E, MFI of IFNg coexpressed on CD161þ CTLs treated with CD161-blocking antibodies for 72 hours in HPVþ biopsies (n ¼ 3) and blood samples (n ¼ 4), paired Student t test. , P < 0.05; , P < 0.01; , P < 0.001. n.s.: no statistical significance.

Article Snippet: For the checkpoint blockade experiment, cryopreservated TILs or PBMCs were thawed, expanded, and seeded (5 105 cells/well) as described, and treated with PD-1 blocking monoclonal antibody (mAb; BioLegend, clone EH12.2H7, cat. #329926, 10 mg/mL), CD39 blockingmAb (Bio-Rad, clone A1, cat. #MCA1268EL, 10 mg/mL), or Tim-3 blocking mAb (BioLegend, clone F28-2E2, cat. #345004, 10 mg/mL) for 7 days.

Techniques: Expressing, RNA Sequencing, Cytometry, Blocking Assay

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Expression Patterns of B7-H3 and CD39 in Gastric Precancerous Lesions and Gastric Cancer Tissues. (A) Representative IHC Expression Patterns of B7-H3 and CD39 Across Different Pathological Stages (CSG, CAG, LGIN, HGIN, and GC). (B) Quantitative Analysis of Positive Expression Areas of CD39. (C) Quantitative Analysis of Positive Expression Areas of B7-H3. (D) Representative Multiplex IHC Expression Patterns of B7-H3 and CD39 Across Different Pathological Stages (CSG, CAG, LGIN, HGIN, and GC). (E) Quantitative Analysis of Multiplex IHC Expression of B7-H3 and CD39. (F) Representative Co-Localization Expression of B7-H3 and CD39 in GC. IHC Scale Bars: 50 µm; mIHC Scale Bars: 100 µm.

Article Snippet: The following primary antibodies were used according to the manufacturer's instructions: mouse anti-human B7-H3 monoclonal antibody, 1/200 dilution (Cat No: 66 481-1-Ig, Proteintech, China), rabbit anti-human CD39 polyclonal antibody, 1/1000 dilution (Cat No: 14211-1-AP, Proteintech, China) and mouse anti-human CD8 monoclonal antibody, 1/10 000 dilution (Cat No: 66868-1-Ig, Proteintech, China).

Techniques: Expressing, Multiplex Assay

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Co-Localization of B7-H3 and CD39 in Gastric Cancer Cells Indicates Poor Prognosis. (A, B) Representative Immunohistochemical Images Showing Low and High Expression of B7-H3 (A) and CD39 (B) in Gastric Cancer (GC) Specimens. (C) Correlation Analysis of B7-H3 and CD39 Expression. (F, G, H, I) Kaplan-Meier Survival Curves for Overall Survival of GC Patients Based on the Expression Status of B7-H3 (F), CD39 (G), Dual High Expression of B7-H3 and CD39 (H), and Co-Localized Expression Status of B7-H3-CD39 (I). Scale Bars: 100 µm.

Article Snippet: The following primary antibodies were used according to the manufacturer's instructions: mouse anti-human B7-H3 monoclonal antibody, 1/200 dilution (Cat No: 66 481-1-Ig, Proteintech, China), rabbit anti-human CD39 polyclonal antibody, 1/1000 dilution (Cat No: 14211-1-AP, Proteintech, China) and mouse anti-human CD8 monoclonal antibody, 1/10 000 dilution (Cat No: 66868-1-Ig, Proteintech, China).

Techniques: Immunohistochemical staining, Expressing

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Absence of Correlation Between Co-localization of B7-H3 and CD39 Expression and CD8 + T Cell Infiltration in Gastric Cancer. (A, B) Representative Immunohistochemical Images Showing the Expression of B7-H3 with CD8 (A) or CD39 with CD8 (B) in the Same Patient. (C) Correlation Between B7-H3 Expression and CD8 Expression, and Between CD39 Expression and CD8 Expression. (D, E) Representative Multiplex Immunohistochemistry Images of B7-H3, CD39, and CD8 (D), and Correlation Analysis Between the Co-Localization Expression Score of B7-H3 and CD39 and the Extent of CD8 Infiltration (E). (F, G) Representative Multiplex Immunohistochemistry Images of CD39 and CD8, with Arrows Indicating CD39 + CD8 + T Cells (F), and the Proportion of CD39 + CD8 + T Cells within the CD8 + T Cell Population (G). Scale Bars: 100 µm.

Article Snippet: The following primary antibodies were used according to the manufacturer's instructions: mouse anti-human B7-H3 monoclonal antibody, 1/200 dilution (Cat No: 66 481-1-Ig, Proteintech, China), rabbit anti-human CD39 polyclonal antibody, 1/1000 dilution (Cat No: 14211-1-AP, Proteintech, China) and mouse anti-human CD8 monoclonal antibody, 1/10 000 dilution (Cat No: 66868-1-Ig, Proteintech, China).

Techniques: Expressing, Immunohistochemical staining, Multiplex Assay, Immunohistochemistry

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Kaplan-Meier Survival Curves for Gastric Cancer Patients Based on Specific Expression Statuses and Immune Cell Infiltration Levels. (A, B, C, D) Kaplan-Meier Survival Curves for GC Patients Stratified by B7-H3 High CD8 Low (A) Expression Status 、 CD39 High CD8 Low (B) Expression Status 、 B7-H3-CD39 Both high CD8 Low Expression Status (C) and B7-H3-CD39 Co-localization CD8 low Expression Status (D). (E, F) Kaplan-Meier Survival Curves for GC Patients Based on CD8 + T Cell Infiltration Levels (E) and CD39 + CD8 + T Cell Infiltration Status (F).

Article Snippet: The following primary antibodies were used according to the manufacturer's instructions: mouse anti-human B7-H3 monoclonal antibody, 1/200 dilution (Cat No: 66 481-1-Ig, Proteintech, China), rabbit anti-human CD39 polyclonal antibody, 1/1000 dilution (Cat No: 14211-1-AP, Proteintech, China) and mouse anti-human CD8 monoclonal antibody, 1/10 000 dilution (Cat No: 66868-1-Ig, Proteintech, China).

Techniques: Expressing